drugset / Trial / NCT03689582

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

NCT03689582

Phase 2 Terminated 11 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of the study is to find out whether imaging of the prostate with a new molecule called 68Ga-PSMA can find prostate cancer. 68Ga-PSMA has been shown in a large number of patients to be useful to find recurring prostate cancer following initial cancer treatment. This study is performed to test 68Ga-PSMA whether it can be used to find prostate cancers that would be considered in need for treatment.

Timeline

Start
2018-11-13
Primary completion
2020-02-27
Completion
2020-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 185 mbq Intravenous

Indications